The prevalence of primary aldosteronism in diabetic patients
| Autor: | Susan Steigerwalt, Margaret Fadanelli, Naushaba Mohiuddin, Dijana Jefic, Rana Alsabbagh |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism Urology Diabetic angiopathy Plasma renin activity chemistry.chemical_compound Primary aldosteronism Internal medicine Diabetes mellitus Hyperaldosteronism Renin Internal Medicine medicine Prevalence Humans Aldosterone Creatinine business.industry food and beverages Middle Aged medicine.disease Original Papers Endocrinology chemistry Diabetes Mellitus Type 2 Hypertension Spironolactone Female Cardiology and Cardiovascular Medicine business Diabetic Angiopathies |
| Zdroj: | J Clin Hypertens (Greenwich) |
| ISSN: | 1524-6175 |
| Popis: | Increased plasma aldosterone concentrations (PACs) are associated with higher cardiovascular risk and target organ damage (TOD). Hyperglycemia can potentiate the cellular effects of aldosterone, and the prevalence of diabetes in primary aldosteronism (PA) is 7%–59%. The prevalence of PA in hypertensive individuals is estimated to be 10%–14%. This study of 61 hypertensive diabetic patients not taking spironolactone and with serum creatinine values 15 ng/dL and plasma renin activity was 30). Although 14 patients had suppressed renin with PACs >8 ng/ dL (including two with PACs >11 ng/dL), none met our criteria for PA. There was no correlation between PAC and TOD. This study indicates that routine screening for PA in hypertensive diabetic patients is not justified and that PAC does not correlate with TOD. Further study is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|